Caplin Point Share: Shares of Caplin Point Laboratories Limited have gained more than 3 percent today, January 7. At present this stock is trading at Rs 2559.15 with a gain of 1.96 percent on BSE. In fact, the US Food and Drug Administration (USFDA) has approved the manufacturing facility of the company’s injectable and ophthalmic drugs with zero observations. This facility is located in Gummidipundi, Tamil Nadu. After this news, the shares of the company are being bought. With today’s rise, the market cap of the company has increased to Rs 19452 crore.
The US drug regulator (USFDA) had inspected the facility in Gummidipundi between August 5 and 9 without any prior notice. This inspection is part of the FDA’s routine process to ensure compliance with Good Manufacturing Practices and other regulatory requirements in a company’s manufacturing process.
Caplin Point Laboratories reported 14.04 per cent growth in its consolidated net profit at Rs 130.80 crore in the July-September quarter. On the other hand, revenue increased by 17.81 per cent to Rs 483.10 crore in Q2 FY25. EBITDA margin improved slightly to 36.8 per cent in Q2 FY25, compared to 36.7 per cent in the same quarter last fiscal.
Caplin Point shares have gained 7 percent in the last one month. The stock has given a return of 79 percent in the last 6 months. At the same time, its investors have made a profit of 83 percent in the last one year.
Disclaimer: The information provided here is for information only. It is important to mention here that investing in the market is subject to market risks. As an investor, always consult an expert before investing money. Moneycontrol never advises anyone to invest money here.